380 results match your criteria dysthyroid optic


Retinal nerve fiber layer thickness measured by optical coherence tomography predicts visual recovery after orbital decompression for dysthyroid optic neuropathy.

Int Ophthalmol 2021 May 4. Epub 2021 May 4.

Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Road 1277, Wuhan, 430022, Hubei Province, China.

Purpose: To determine the prognostic value of optical coherence tomography (OCT) measurement of the peripapillary retinal nerve fiber layer (RNFL) thickness in visual recovery after orbital decompression of patients with dysthyroid optic neuropathy (DON).

Methods: A total of 52 eyes of 37 patients who underwent orbital decompression for DON between 2013 and 2019 were retrospectively reviewed. We examined peripapillary RNFL thickness, best-corrected visual acuity (BCVA), visual field (VF) for mean deviation (MD) and pattern standard deviation (PSD), and pattern-reversed visual evoked potential (PVEP) for P100 latency and amplitude before and after surgery. Read More

View Article and Full-Text PDF

Modified endoscopic transnasal orbital apex decompression in dysthyroid optic neuropathy.

Eye Vis (Lond) 2021 Apr 28;8(1):19. Epub 2021 Apr 28.

The Eye Hospital of Wenzhou Medical University, No. 270 Xueyuan Xi Road, Wenzhou, Zhejiang, 325027, P. R. China.

Background: To describe the surgical technique and assess the clinical efficacy and safety of modified endoscopic transnasal orbital apex decompression in the treatment of dysthyroid optic neuropathy.

Methods: In this retrospective research, forty-two subjects (74 orbits) who underwent modified endoscopic transnasal orbital apex decompression for the treatment of dysthyroid optic neuropathy were enrolled. Preoperative and postoperative best-corrected visual acuity (BCVA), visual field mean deviation (MD), Hertel exophthalmometry, and new onset diplopia were assessed before and after the intervention. Read More

View Article and Full-Text PDF

Graves' Orbitopathy: Report of 82 cases.

Tunis Med 2021 Feb;99(2):243-251

Introduction: Graves' disease (GD) is a common autoimmune disorder. Graves'orbitopathy (GO) is its most common extrathyroidal manifestation. It is rare but may reveal the disease. Read More

View Article and Full-Text PDF
February 2021

Α Case of Severe Thyroid Eye Disease Treated with Tocilizumab.

Acta Medica (Hradec Kralove) 2021 ;64(1):64-69

University Eye Clinic, University Hospital of Alexandroupolis, Greece.

This is a case report describing a patient with severe thyroid eye disease complicated with dysthyroid optic neuropathy that was unresponsive to intravenous steroids and orbital radiotherapy but responded well to intravenous tocilizumab. Read More

View Article and Full-Text PDF
January 2021

RAGE and HMGB1 Expression in Orbital Tissue Microenvironment in Graves' Ophthalmopathy.

Mediators Inflamm 2021 11;2021:8891324. Epub 2021 Mar 11.

Department of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland.

Graves' ophthalmopathy (GO) is a chronic autoimmune inflammatory disorder involving orbital tissues. A receptor for advanced glycation end products (RAGE) and its ligand high mobility group box 1 (HMGB1) protein trigger inflammation and cell proliferation and are involved in the pathogenesis of various chronic inflammatory diseases. This study was aimed to evaluate RAGE and HMGB1 expression in GO to determine its potential clinical significance. Read More

View Article and Full-Text PDF

Early Experience With the Clinical Use of Teprotumumab in a Heterogenous Thyroid Eye Disease Population.

Ophthalmic Plast Reconstr Surg 2021 Mar 8. Epub 2021 Mar 8.

Division of Orbital and Ophthalmic Plastic Surgery, Jules Stein Eye Institute, University of California, Los Angeles, California, U.S.A.

Purpose: To describe the clinical course in a heterogeneous series of subjects with thyroid eye disease (TED) treated with teprotumumab.

Methods: Cross-sectional cohort study including patients with clinical diagnosis of TED who was treated with teprotumumab. The entire cohort was analyzed together and subsequently in clinical subgroups based on stage and grade of disease. Read More

View Article and Full-Text PDF

Comparison of 2-wall versus 3-wall orbital decompression against dysthyroid optic neuropathy in visual function: A retrospective study in a Chinese population.

Medicine (Baltimore) 2021 Feb;100(8):e24513

Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Abstract: To compare visual function of 2-wall (medial and lateral) versus 3-wall (medial, lateral, and inferior) orbital decompression in patients with dysthyroid optic neuropathy (DON).A total of 52 eyes of 37 patients underwent orbital decompression for DON between 2013 and 2019 were retrospectively reviewed. Two- or 3-wall decompression was performed in 31 eyes of 23 patients and 21 eyes of 14 patients, respectively. Read More

View Article and Full-Text PDF
February 2021

Thyroid-Associated Ophthalmopathy: Preliminary Study Using T2 Mapping to Characterize Intraorbital Optic Nerve Changes Before Dysthyroid Optic Neuropathy.

Endocr Pract 2021 Mar 23;27(3):191-197. Epub 2020 Dec 23.

Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address:

Objective: To evaluate the performance of T2 mapping in detecting intraorbital optic nerve (ON) changes in patients with thyroid-associated ophthalmopathy (TAO) before the onset of dysthyroid optic neuropathy (DON).

Methods: Thirty-five patients with TAO and without DON (21 active, 14 inactive) and 21 healthy controls (HCs) were enrolled. Magnetic resonance imaging-derived parameters of T2 relaxation time (T2RT) at the intraorbital ON, extraocular muscle (EOM), orbital fat, exophthalmos, summed thickness of EOMs, orbital fat thickness, and clinical variables were compared. Read More

View Article and Full-Text PDF

Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.

Eur J Ophthalmol 2021 Feb 1:1120672121991042. Epub 2021 Feb 1.

Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, OH, USA.

Thyroid eye disease is an auto-immune mediated orbitopathy which can cause dysthyroid compressive optic neuropathy. Traditional management of active thyroid eye disease includes temporizing high-dose steroids, orbital radiation and surgical decompression, which each possess significant limitations and/or side effects. Teprotumumab is an IGF-IR inhibitor recently FDA-approved for active thyroid eye disease. Read More

View Article and Full-Text PDF
February 2021

Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy.

Eur Thyroid J 2020 Dec 10;9(Suppl 1):17-30. Epub 2020 Aug 10.

Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany.

Background: Both Graves' hyperthyroidism (GH) and Graves' orbitopathy (GO) are associated with significant adverse health consequences. All conventional treatment options have limitations regarding efficacy and safety. Most importantly, they do not specifically address the underlying immunological mechanisms. Read More

View Article and Full-Text PDF
December 2020

Pterional Orbit Decompression in Grave Disease with Dysthyroid Optic Neuropathy.

World Neurosurg 2021 May 19;149:e1007-e1016. Epub 2021 Jan 19.

Department of Neurosurgery, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address:

Objective: The choice of surgical technique in sight-threatening Grave orbitopathy remains controversial. Available data are mostly derived from mixed cohorts with multiple surgical indications and techniques. The authors assessed predictors for visual outcome after standardized pterional orbital decompression for dysthyroid optic neuropathy. Read More

View Article and Full-Text PDF

[Efficacy of transethmoidal orbital decompression in patients with dysthyroid optic neuropathy].

Vestn Otorinolaringol 2020 ;85(6):52-55

I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovskiy University), Moscow, Russia.

Objectives: To estimate efficacy and safety of endoscopic orbital decompression in patients with dysthyroid optic neuropathy (DON).

Material And Methods: 19 patients aged 54.8±7. Read More

View Article and Full-Text PDF
January 2021

Single-stage Orbital Decompression, Strabismus and Eyelid Surgery in Moderate to Severe Thyroid Associated Orbitopathy.

Orbit 2021 Jan 3:1-9. Epub 2021 Jan 3.

ENT Department, Villa Tiberia Hospital - GVM Care & Research, Rome, Italy.

: To evaluate the outcome of orbital decompression, strabismus and/or eyelid surgery in patients with moderate to severe thyroid-associated orbitopathy, when combined approach is preferred.: Retrospective, comparative, non-randomized review of 45 patients operated on from 2015 to 2018. Simultaneous decompression, eyelid and/or strabismus surgery was performed in 34 eyes of 20 subjects (group 1). Read More

View Article and Full-Text PDF
January 2021

Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment.

Curr Opin Neurol 2021 Feb;34(1):116-121

Department of Ophthalmology and Visual Sciences, Illinois Center for Thyroid Eye Disease, Illinois Eye and Ear Infirmary UIC, Chicago, Illinois, USA.

Purpose Of Review: Thyroid eye disease (TED) is a disfiguring disease that can lead to neuro-ophthalmic manifestations including diplopia and optic neuropathy. The aim of this review is to shed light on the diagnosis of TED based on clinical examination findings and diagnostic imaging. We will also discuss gold standard as well as newly emerging therapies for TED. Read More

View Article and Full-Text PDF
February 2021

Sight-Threatening Graves' Ophthalmopathy during the Third Trimester of Pregnancy: A Case Report.

Tohoku J Exp Med 2020 12;252(4):321-327

Department of Endocrinology and Metabolism, National Hospital Organization Sendai Medical Center.

Dysthyroid optic neuropathy is a severe manifestation of Graves' ophthalmopathy that can result in permanent vision loss. We report a 37-year-old pregnant woman with Graves' ophthalmopathy which was deteriorated to dysthyroid optic neuropathy in the third trimester of pregnancy. Diplopia, bilateral eye lid retraction, lid edema and proptosis were observed in the 29th week of gestation. Read More

View Article and Full-Text PDF
December 2020

Systemic evaluation of patients with central serous chorioretinopathy: A case-control study.

Eur J Ophthalmol 2020 Nov 25:1120672120975698. Epub 2020 Nov 25.

Department of Ophthalmology, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.

Objective: To investigate the systemic associations of central serous chorioretinopathy (CSCR) with help of clinical and biochemical investigations.

Design: Case-control study.

Participants: Eighty seven CSCR patients (case) and 82 Asian-Indian patients with primary non-traumatic rhegmatogenous retinal detachment (control) were recruited between July 2017 and December 2018 at a tertiary eye-care center in North India. Read More

View Article and Full-Text PDF
November 2020

Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.

Thyroid 2021 May 31;31(5):821-828. Epub 2021 Mar 31.

Department of Clinical Sciences and Community Health, Graves' Orbitopathy Center, Endocrinology, Milan, Italy.

Rituximab (RTX), a chimeric human-murine anti-CD20 monoclonal antibody, has been used for treatment of active moderate-severe Graves' orbitopathy (GO) since 2004 as second-line therapy in patients unresponsive to intravenous steroids. We conducted an open-label prospective study (EUDRACT 2012-001980-53) in which patients were treated with a single infusion of only 100 mg RTX to analyze the efficacy and safety of this low dose. Seventeen patients, of whom nine had disease that was unresponsive to intravenous methylprednisolone and eight with newly diagnosed GO, were enrolled. Read More

View Article and Full-Text PDF

Use of Rituximab After Orbital Decompression Surgery in Two Grave's Ophthalmopathy Patients Progressing to Optic Neuropathy.

Front Endocrinol (Lausanne) 2020 26;11:583565. Epub 2020 Oct 26.

Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background: While orbital decompression can alleviate optic nerve compression and prevent further vision loss in dysthyroid optic neuropathy (DON), it cannot relieve inflammatory symptoms. Very high doses of intravenous glucocorticoids (GCs) are the first-line therapy for DON; however, the effective rate is only 40% and might be much lower in patients who fail high-dose GC pulse therapy and progressed to DON. The results of two case series studies indicated that rituximab treatment had a much better curative effect compared to very high doses of intravenous GCs, but some patients required urgent orbital decompression after rituximab injection because rituximab might lead to the release of cytokines, aggravated intraorbital edema, and further vision loss. Read More

View Article and Full-Text PDF
October 2020

Comparing isolated-check visual evoked potential, pattern visual evoked potential, and standard automated perimetry in dysthyroid optic neuropathy eyes.

Eye (Lond) 2020 Nov 13. Epub 2020 Nov 13.

Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.

Objective: To determine the diagnostic ability of isolated-check visual evoked potential (icVEP), pattern visual evoked potential (pVEP), and standard automated perimetry (SAP) between dysthyroid optic neuropathy (DON) and thyroid-associated ophthalmopathy (TAO) without DON (non-DON).

Methods: This is a case-control study, 49 bilateral patients (26 DON and 23 non-DON) were included. icVEP, pVEP, and SAP were conducted in all the subjects, icVEP parameters compared were signal-to-noise ratios (SNRs) under 8, 16, and 32% depth of modulation (DOM). Read More

View Article and Full-Text PDF
November 2020

[Peripapillary and macular vessel density in eyes with different phases of thyroid-associated ophthalmopathy].

Zhonghua Yan Ke Za Zhi 2020 Nov;56(11):824-831

Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, ChinaWang Yuhan is now working at Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.

To analyze the characteristics of vessel density in the optic disc and macular area of patients with different phases of thyroid-associated ophthalmopathy (TAO) and their correlation with visual function. This case-control study was conducted at the Department of Ophthalmology of Peking Union Medical College Hospital between June 2019 and September 2019. TAO patients and healthy volunteers were included in the study. Read More

View Article and Full-Text PDF
November 2020

Abnormal functional connectivity density in patients with dysthyroid optic neuropathy.

Ophthalmic Res 2020 Nov 3. Epub 2020 Nov 3.

[Objective] Functional connectivity density (FCD) mapping was used to investigate abnormalities and factors related to brain functional connectivity (F.C.) in cortical regions of patients with dysthyroid optic neuropathy (DON) and to analyze the pathogenesis of DON further. Read More

View Article and Full-Text PDF
November 2020

Sight-Threatening Thyroid Eye Disease: Role of Diabetes Mellitus and Interaction with Other Risk Factors.

Ophthalmic Plast Reconstr Surg 2020 Oct 8. Epub 2020 Oct 8.

Clinical Epidemiology and Bio-Statistics, L V Prasad Eye Institute, KAR campus, Hyderabad, India.

Purpose: The aim of the study was to investigate whether diabetes mellitus (DM) is an independent risk factor in sight-threatening thyroid eye disease (ST-TED) and explore the interaction of DM with other known risk factors in TED.

Methods: This was a retrospective cohort study and included 202 consecutive TED patients presenting between 2013 and 2019. Data collected included demography, history of smoking, thyroid dysmetabolism, and presence of DM, TED-duration, activity and severity, best-corrected visual acuity (BCVA), and follow-up. Read More

View Article and Full-Text PDF
October 2020

How Effective is Superolateral Orbital Decompression in Cases of Drug-Resistant Graves' Ophthalmopathy.

Folia Med (Plovdiv) 2020 Sep;62(3):462-467

Military Medical Academy, Sofia, Bulgaria.

Introduction: Graves' ophthalmopathy (GO) is the most common and difficult-to-treat extrathyroidal symptom of Graves' disease. Though retraction of the upper eyelid is the most common clinical feature of GO, it can have a much more severe clinical manifesta-tion with symptoms such as conjunctival chemosis, keratopathy, extraocular muscle dysfunction, proptosis of the bulb and dysthyroid optic neuropathy. Treatment methods include control of the thyroid function, corticosteroid and immunosuppressive therapy as well as radiotherapy. Read More

View Article and Full-Text PDF
September 2020

Teprotumumab for Dysthyroid Optic Neuropathy: Early Response to Therapy.

Ophthalmic Plast Reconstr Surg 2020 Sep 22. Epub 2020 Sep 22.

Department of Ophthalmology, Byers Eye Institute.

A 45-year-old male presented with active progressive thyroid eye disease refractory to intravenous steroids and right orbital radiation. Visual acuity, left relative afferent pupillary defect, and Humphrey visual field defects were consistent with worsening left dysthyroid optic neuropathy. Orbital MRI demonstrated extraocular muscle enlargement and effacement of the left optic nerve sheath. Read More

View Article and Full-Text PDF
September 2020

Strategies in Surgical Decompression for Thyroid Eye Disease.

Oxid Med Cell Longev 2020 9;2020:3537675. Epub 2020 Sep 9.

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.

Surgical management of thyroid eye disease- (TED-) associated morbidity has been plagued by the complex interplay of different operative techniques. Orbital decompression is the well-recognized procedure for disfiguring exophthalmos and dysthyroid optic neuropathy (DON). There are numerous published techniques described for the removal of the orbital bone, fat, or a combination. Read More

View Article and Full-Text PDF
September 2020

[Dysthyroid optic neuropathy: surgical treatment potential].

Vestn Oftalmol 2020 ;136(4. Vyp. 2):193-200

Research Institute of Eye Diseases, Moscow, Russia.

Purpose: To evaluate the effectiveness of bony orbital decompression in patients with dysthyroid optic neuropathy (DON).

Material And Methods: The study analyzed 255 patients with thyroid eye disease (TED) and bony orbital decompression. Those among them who had DON as an indication for surgery were investigated further. Read More

View Article and Full-Text PDF
September 2020

Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients.

J Clin Med 2020 Aug 31;9(9). Epub 2020 Aug 31.

Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, 39008 Santander, Spain.

Graves' orbitopathy (GO) is the most common extrathyroidal manifestation of Graves' disease (GD). Our aim was to assess the efficacy and safety of Tocilizumab (TCZ) in GO refractory to conventional therapy. This was an open-label multicenter study of glucocorticoid-resistant GO treated with TCZ. Read More

View Article and Full-Text PDF